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Abstract
Background: Daily trimethoprim-sulfamethoxazole (TS) protects against malaria, but efficacy may be diminished as 
anti-folate resistance increases. This study assessed the incidence of falciparum malaria and the prevalence of 
resistance-conferring Plasmodium falciparum mutations in HIV-infected children receiving daily TS and HIV-uninfected 
children not taking TS.
Materials and methods: Subjects were 292 HIV-infected and 517 uninfected children from two cohort studies in 
Kampala, Uganda observed from August 2006 to December 2008. Daily TS was given to HIV-infected, but not HIV-
uninfected children and all participants were provided an insecticide-treated bed net. Standardized protocols were 
used to measure the incidence of malaria and identify markers of antifolate resistance.
Results: Sixty-five episodes of falciparum malaria occurred in HIV-infected and 491 episodes in uninfected children 
during the observation period. TS was associated with a protective efficacy of 80% (0.10 vs. 0.45 episodes per person 
year, p < 0.001), and efficacy did not vary over three consecutive 9.5 month periods (81%, 74%, 80% respectively, p = 
0.506). The prevalences of dhfr 51I, 108N, and 59R and dhps 437G and 540E mutations were each over 90% among 
parasites infecting both HIV-infected and uninfected children. Prevalence of the dhfr 164L mutation, which is 
associated with high-level resistance, was significantly higher in parasites from HIV-infected compared to uninfected 
children (8% vs. 1%, p = 0.001). Sequencing of the dhfr and dhps genes identified only one additional polymorphism, 
dhps 581G, in 2 of 30 samples from HIV-infected and 0 of 54 samples from uninfected children.
Conclusion: Despite high prevalence of known anti-folate resistance-mediating mutations, TS prophylaxis was highly 
effective against malaria, but was associated with presence of dhfr 164L mutation.
Background
Daily prophylaxis with the anti-folate combination
trimethoprim-sulphamethoxazole (TS) has been shown
to reduce morbidity and improve survival in HIV-
infected populations [1,2]. In addition to the prevention
of opportunistic and other common bacterial infections
associated with HIV infection, TS reduces the risk of
malaria in HIV-infected adults and children living in sub-
Saharan Africa [1,3-5]. The World Health Organization,
UNAIDS and UNICEF recommend TS prophylaxis for all
HIV-infected patients with symptomatic disease (WHO
Stage 2, 3, and 4), Stage 1 HIV-infected adults with CD4
lymphocyte counts less than 350 cells/μl, Stage 1 HIV-
infected children with CD4 lymphocyte percentage less
than 25%, and all infants born to HIV-infected mothers
(HIV-exposed) [6].
Despite the evidence for significant benefits associated
with TS use in HIV-infected patients, implementation of
TS prophylaxis in sub-Saharan Africa remains low. A
recent UNICEF report estimated that only 4% of the 4
million children in need of TS prophylaxis in sub-Saharan
Africa are receiving this intervention [7]. There are con-
cerns that in areas where anti-folate resistance is exten-
sive, TS may not be effective in preventing malaria and
bacterial infections, while in areas where resistance is not
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yet widespread, expanded TS use may lead to the rapid
selection and spread of Plasmodium falciparum parasites
resistant to anti-folates. This in turn may diminish the
preventive efficacy of TS and sulphadoxine-
pyrimethamine (SP), which acts against the same two
enzyme targets as TS. Cross-resistance between TS and
SP is of particular concern as, although SP is being
replaced by more effective agents for the treatment of
malaria, it remains the only recommended drug for inter-
mittent preventive therapy (IPT), a validated measure to
prevent malaria in pregnant women [8].
To characterize the risks and benefits of daily TS, this
study compared the incidence of malaria and the preva-
lence of anti-folate resistance-conferring mutations in P.
falciparum infections in HIV-uninfected children not
taking TS and HIV-infected children taking daily TS in an
area of moderate malaria transmission. Further, the effect
of time on the protective efficacy of TS and the preva-
lence of anti-folate resistance-conferring mutations was
evaluated.
Methods
Study site
The study was carried out in Kampala, Uganda. Kampala
is an urban setting in south-central Uganda where
malaria is mesoendemic, occurring perennially with
peaks following two rainy seasons, and an entomological
inoculation rate (EIR) estimated to be less than 10 infec-
tive bites per person year in 2005 (unpublished data).
Study subjects
Subjects were children participating in two parallel
cohort studies, which have been described previously
[4,9] and are summarized here briefly. The first study
enrolled 599 healthy children presumed to be HIV-unin-
fected (432 tested HIV negative, 167 HIV test results
unavailable; all subjects were healthy) into a community-
based cohort from a geographically defined census popu-
lation using probability sampling from November 2004
through April 2005. Eligibility criteria included: 1) age 1-
10 years, 2) agreement to come to the study clinic for any
febrile episode or other illness, 3) agreement to remain in
Kampala for the duration of the study, 4) agreement to
avoid medications administered outside the study proto-
col, 5) lack of history of any known serious chronic dis-
ease requiring frequent medical attention, including
HIV/AIDS, 6) weight >10 kg, and 7) provision of
informed consent from parent or guardian. None of the
HIV-uninfected cohort study participants were pre-
scribed TS prophylaxis. All study participants were given
an insecticide treated bed net (ITN) between May-June
2006. The second study enrolled 300 HIV-infected chil-
dren from a pediatric HIV clinic in Kampala from Octo-
ber 2005 through August 2006 using convenience
sampling. Eligibility criteria were the same as for the
HIV-uninfected cohort, except for: 1) living within a 20
km radius of the study clinic, 2) no restriction based on a
history of serious chronic disease, and 3) weight >5 kg.
All HIV-infected cohort participants were prescribed
daily TS and provided with an ITN at enrollment.
Study participant follow-up
Similar protocols were used for follow-up of both
cohorts. Subjects were followed for all of their medical
problems in dedicated study clinics open seven days a
week, with after hours care available at Mulago Hospital.
Children who presented with new medical problems
underwent standardized medical evaluation. A set of
algorithms was developed to guide therapy for common
illnesses. Medications with anti-malarial activity were
avoided for the treatment of non-malarial illnesses when
possible. HIV-infected subjects meeting standard WHO
eligibility criteria were provided antiretroviral therapy
according to local guidelines[10]. The preferred first line
therapy for those initiated to ART was Efavirenz (EFV),
lamivudine (3TC) and zidovudine (AZT). Subjects who
presented to the clinics with a documented fever (tym-
panic temperature >38.0°C) or history of fever in the pre-
vious 24 hours had blood obtained by fingerprick for a
thick blood smear. If the thick blood smear was positive,
the patient was diagnosed with malaria regardless of the
parasite density. HIV-uninfected participants diagnosed
with uncomplicated malaria were assigned randomly to anti-
malarial treatment with sulphadoxine-pyrimethamine
plus amodiaquine (SP + AQ), amodiaquine plus artesu-
nate (AQ + AS), or artemether-lumefantrine (AL). HIV-
infected children were treated with AQ + AS between
August 2006 and June 2007. Use of AQ + AS in this study
was stopped after a high risk of neutropaenia secondary
to malaria treatment was observed [11]; it was replaced
with AL from July 2007 to the end of the study. All epi-
sodes of complicated malaria and treatment failures
occurring within 14 days of initial therapy were treated
with quinine.
TS adherence in HIV-infected participants was mea-
sured during routine monthly visits using caregivers' self-
report of administering drugs during the previous 3 days.
Study participants were withdrawn from follow-up if
any of the following occurred: 1) movement out of study
area for >60 consecutive days, 2) inability to be located
for >60 consecutive days, 3) withdrawal of informed con-
sent, or 4) inability to adhere to study schedule and pro-
cedures.
Laboratory methods
Thick smears were stained with 2% Giemsa for 30 min-
utes. Parasite density was estimated by counting the
number of asexual parasites per 200 white blood cells and
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calculating parasites per μL, assuming a white blood cell
count of 8,000 cells per μL. A smear was judged to be
negative if no parasites were seen after review of 100
high-powered fields. Final microscopy results were based
on a rigorous quality control system which included re-
reading all blood smears by a second microscopist and
resolution of any discrepancies between the first and sec-
ond readings by a third microscopist. Parasite species on
the day malaria was diagnosed was determined using
nested PCR of 18 S small sub-unit ribosomal DNA as pre-
viously described [12].
For repeat episodes of malaria in the same study partic-
ipant, molecular genotyping was used to distinguish new
from recrudescent infections. DNA was isolated from
blood samples collected on filter paper on the day of
malaria diagnosis, and samples were genotyped in a step-
wise fashion by assessing polymorphisms in msp-2, msp-
1, and four microsatellites as previously described [13]. If,
for any of the six loci, an allele was not shared between
consecutive episodes of malaria, the episode was classi-
fied as a new infection. If at least one allele was shared
between consecutive episodes of malaria at all six loci,
the episode was classified as a recrudescence.
Samples were tested on the day malaria was diagnosed
for the following polymorphisms associated with anti-
folate resistance: dihydrofolate reductase (dhfr) N51I,
C59R, S108N, and I164L; and dihydropteroate synthetase
(dhps) A437G and K540E. Polymorphisms were identi-
fied using a nested polymerase chain reaction followed by
sequence-specific restriction enzyme digestion. Primers,
amplification conditions, and restriction endonucleases
for these assays were as previously described [14,15].
Digestion products were visualized by agarose gel elec-
trophoresis and results were classified according to the
migration patterns of the fragments. Laboratory investi-
gators were blinded to clinical data at the time of molecu-
lar analysis.
For a subset of samples, the complete dhfr and dhps
genes were amplified by nested PCR and sequenced. For
dhfr, the gene was amplified with primers 3A (5'-CCCA-
AATAGCTAGTTCAGGGGAAC and 4B (5'-TCATCT-
TCTTCTTCATCATCATCATC) followed by the nested
primers 3'A (5'-CTCCTTTTTATGATGGAACAAGTC
TGCG) and 3B (5'-TGACATGTATCTTTGTCATCAT
TC) to yield a 785 bp fragment.
For dhps, primers were 6A (5'-GGATCAGAAGAT-
GAATAATCATGT) and 3B (5'-CACTAAACCATTA-
GAGTACTTGAC), followed by 7A (5'-CCATTCCTC
ATGTGTATACAACAC) and 5B (5'-GTTTAATCACAT-
GTTTGCACTTTC-3'), yielding a 1326 bp fragment.
Amplicons were purified using Exosap (USB) and
sequenced bi-directionally using nested primers at the
Genomics Core Facility, UCSF. Sequence data were
aligned and manually curated using Lasergene (DNAS-
TAR).
Statistical analysis
The period of observation began on August 1, 2006
(when enrollment for both cohorts was complete and all
study participants had been given an ITN) and continued
through December 15, 2008 (when follow-up for the
HIV-uninfected cohort ended) or the date of premature
study withdrawal.
Data were entered and verified using Access (Microsoft
Corporation, Redmond, WA). Analyses were performed
using STATA version 10.0 (Stata Corp., College Station,
TX). Log-transformed parasite densities were compared
using the two-sample t-test and categorical variables
(comparisons of mutation prevalence and parasite spe-
cies) were analysed using Fisher exact or chi-square tests.
Malaria incidence was defined as the number of new epi-
sodes of malaria (recrudescences were excluded) per
period of observation. Negative binomial regression
models were used to measure the association between
use of TS prophylaxis and malaria incidence (expressed
as an incidence rate ratio (IRR)), controlling for age. The
protective efficacy of TS was defined as 1 - IRR. Tests for
trend were used to assess for changes in the protective
efficacy of TS and the prevalence of anti-folate resistance-
conferring mutations over the following time periods:
August 1 2006 to May 15 2007; May 16 2007 to February
29 2008 and March 1 2008 to December 15 2008. A p-
value < 0.05 was considered statistically significant.
Ethical approval
Written informed consent was obtained from the par-
ents/guardians of children for their participation in the
study. Ethical approval for the two cohort studies was
obtained from the Uganda National Council of Science
and Technology, Makerere University Research and Eth-
ics Committee, and the University of California, San
Francisco Committee on Human Research.
Results
Study participants
Characteristics of study participants are shown in Table
1. Of the 599 participants enrolled into the HIV-unin-
fected cohort, 517 were still in active follow-up by August
2006 and included in the study. Likewise, 292 of the 300
HIV-infected children initially enrolled were active and
included in the present study. The median level of TS
adherence in the HIV-infected population over the study
period was 100%, with only 216 of 8257 (3%) assessments
associated with less than 100% adherence. The mean age
at the beginning of the observation period was signifi-
cantly higher for HIV-uninfected compared to HIV-
infected participants (7.4 vs. 5.7 years, p < 0.0001), pri-
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marily because the HIV-infected cohort was recruited
about one year later than the uninfected cohort. A total of
452 (87%) HIV-uninfected children and 277 (94%) HIV-
infected children were followed for the full observation
period. The mean CD4 cell percentage in the HIV-
infected cohort was 23% at baseline, 76 (26%) participants
received anti-retroviral therapy (ART) throughout the
study period, and 65 (22%) were initiated on ART during
follow-up.
Characteristics of malaria episodes
The large majority of treatments for malaria were for
new, rather than recrudescent infections, as expected for
cohorts in which malaria episodes were treated with
highly efficacious combination regimens (Table 2).
Ninety-two percent of new malaria episodes were due to
P. falciparum in both HIV-uninfected and HIV-infected
children. The geometric mean parasite density of malaria
infections was lower for HIV-infected (6,462 parasites/μl)
compared to HIV-uninfected (11,270 parasites/μl) chil-
dren, however this difference was not statistically signifi-
cant (p = 0.397).
Malaria incidence
The protective efficacy of TS for the entire observation
period was 80% (95% CI 72-85%) adjusting for age at the
start of the study, and efficacy did not decline over the 3
consecutive 9.5-months periods that constituted the
observation period [IRRs: 0.19 (0.12-0.28), 0.26 (0.15-
0.43) and 0.20 (0.10-0.38), respectively (Table 3)]. The
protective efficacy of TS was similar for HIV-infected
participants receiving [76% (95% C.I. 63-84%)] and not
receiving ART [83% (95% C.I 74-89%)].
Prevalence of resistance-mediating polymorphisms
In new P. falciparum infections, the prevalences of five
dhfr and dhps point mutations known to mediate dimin-
ished response to therapy with SP and to be common in
Table 1: Patient characteristics
Characteristics HIV-uninfected* HIV-infected*
Number of subjects 517 292
Total person years of observation 1095 665
Median duration of follow up in yrs (range) 2.1(0.2-2.4) 2.4 (0-2.4)
Mean age in yrs at the start of follow-up (SD) 7.4 (2.7) 6.0(2.6)
Mean CD4 percent at start of follow-up (SD) N/A 23%(8.6)
Antiretroviral (ART) use during follow-up
Total person years on ART N/A 275
Number of participants on ART at start of follow-up N/A 76 (26%)
Number of participants initiated on ART during follow-up N/A 65 (22%)
*All HIV-uninfected children were not receiving TS while all HIV-infected children were receiving daily TS
Table 2: Characteristics of malaria episodes
Characteristics HIV-uninfected*
(n = 517)
HIV-infected*
(n = 292)
Number of treatments for malaria 511 65
New episodes of malaria† 491 65
Species for new episodes
P. falciparum‡ 451 (92%) 60 (92%)
P. malariae 23 (4%) 2 (3%)
P. ovale 14 (3%) 3 (5%)
P. vivax 3 (1%) 0
Geometric means parasite density per μL§ 11230 6462
* All HIV-uninfected participants were not receiving TS and all HIV-infected participants were receiving daily TS
† After exclusion of episodes due to recrudescences identified by genotyping
‡ Includes P. falciparum mono and mixed infections
§ Only include new episodes of falciparum malaria
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East Africa [16] (dhfr 51I, 108N, and C59R and dhps 437G
and 540E) were all over 90%, independent of TS use
(Table 4) and time. The simultaneous presence of all 5 of
these mutations was also common for HIV-uninfected
and infected participants (86% vs. 92%, p = 0.222) and
prevalence did not increase significantly over the 3 con-
secutive 9.5-month periods in HIV-infected (96%, 86%,
93% respectively, p = 0.446) or uninfected (82%, 89%, 88%
respectively, p = 0.467) participants.
In contrast to the mutations noted above, dhfr 164L,
which has been associated with high-level SP resistance,
was uncommon. Of note, this mutation was significantly
more common in HIV-infected compared to HIV-unin-
fected participants (8% vs. 1%, p = 0.001). As with the
other mutations, prevalence of the dhfr 164L mutation
did not change with time in parasites from HIV-infected
(12%, 10%, 0% p = 0.417) or uninfected participants (0%,
2%, 0%, p = 0.375).
To assess for novel mutations in the dhfr or dhps genes
as a result of daily TS use, the complete genes were
sequenced in a subset of samples, including dhfr from 40
and dhps from 30 HIV-infected children receiving TS and
dhfr from 73 and dhps from 54 uninfected children not
receiving TS. Sequencing confirmed the sequences at
known polymorphic alleles in all samples but one, in
which dhfr 108N/51I/164L mutations were seen in the
initial analysis and 108N/51I/59R seen with sequencing;
presumably the discrepancy was due to characterization
of different strains in a mixed infection. Sequencing iden-
tified only one additional polymorphism, the previously
reported dhps 581G mutation, which was seen in samples
from 2 of 30 children receiving daily TS and none of the
54 HIV-uninfected children for whom sequence results
were available (p = 0.125).
Discussion
The presence of simultaneous cohorts including HIV-
infected children receiving daily TS and HIV-uninfected
children not receiving TS allowed for the assessment of
the anti-malarial preventive efficacy of TS. Results from
Table 3: Comparison of malaria incidence
Time Period HIV-uninfected HIV-infected IRR (95% C.I)
Episodes Person time (yrs) Incidence Episodes Person time Incidence
Aug 1st 06 - Dec 15th 08 491 1095 0.45/psnyr 65 665 0.10/psnyr 0.20 (0.15-0.28)
Aug 1st 06 - May 15th 07 267 397 0.67/psnyr 28 224 0.13/psnyr 0.19 (0.12-0.28)
May 16th 07 - Feb 29th 08 132 364 0.36/psnyr 23 222 0.10/psnyr 0.26 (0.15-0.43)
Mar 1st 08 - Dec 15th 08 92 334 0.28/psnyr 14 220 0.06/psnyr 0.20 (0.10-0.38)
*Incident Rate Ratio controlling for age at beginning each observation period
Table 4: Prevalence of molecular markers of anti-folate resistance among new episodes of P. falciparum malaria
Characteristics HIV-uninfected*
(n = 352)
HIV-infected*
(n = 60)
P-value
Prevalence of dhfr mutations
51I 179(99%)† 60(100%) 0.563
59R 163 (91%)† 56(93%) 0.510
108N 180(100%)† 60 (100%)
164L 1 (1%)† 5 (8%) 0.001
Prevalence of dhps mutations
437G 172 (96%)† 58 (97%) 0.709
540E 174(97%)† 59 (99%) 0.506
Quintuple mutation‡ 154 (86%)† 55 (92%) 0.222
*All HIV-uninfected participants were not receiving TS and all HIV-infected participants were receiving daily TS
† Assessed in a random sample of 180 episodes matched by malaria treatment and calendar time
‡ dhfr 51I/59R/108N + dhps 437G/540E mutations
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this study show that daily TS was highly efficacious in
conferring protection against malaria in HIV-infected
children despite a high prevalence of resistance-mediat-
ing P. falciparum polymorphisms. This study adds to a
previous one by this group which reported a 97% reduc-
tion in malaria risk in HIV-infected children associated
with the combined use of TS and ITNs [4]. In the present
study, without the confounder of ITN use in only the
HIV-infected children, the protective efficacy of daily TS
was more clearly defined, and it remained high.
TS use has recently been shown to protect against
malaria in adults [3] and children [4] in Uganda, but it has
not been clear if continued protection will be seen with
increasing prevalence of mutations in the target enzymes
dhfr and dhps that limit anti-malarial treatment efficacy
of the related anti-folate SP [17-20]. However, in the pres-
ent study, despite some of the highest prevalences of 5
key dhfr and dhps mutations reported in Africa, TS
offered strong protective efficacy against malaria, and
protective efficacy was maintained throughout the 29-
month observation period.
Drugs that inhibit the folate pathway enzymes dhfr and
dhps have important roles in the treatment of many infec-
tions. TS is active against many bacteria and opportunis-
tic pathogens, leading to recommendations for its
widespread use in HIV-infected and exposed individuals
in Africa. SP, which inhibits the same two enzymes as TS,
has been a standard anti-malarial therapy in Africa. Use
of SP to treat malaria is now discouraged due to increas-
ing resistance, especially in Southern and East Africa,
with resistance mediated by step-wise selection and also
selective sweeps of 5 key mutations [21]. Additional
mutations in dhfr and dhps, notably dhfr 164L, mediate
higher levels of resistance, but these mutations are
uncommon in Africa [22]. Despite decreasing malaria
treatment efficacy, SP retains a key role in malaria con-
trol, as it is the only drug well-established to protect
against malaria when used as IPT in pregnant women
[23] or infants [24]. In summary, the anti-folates TS and
SP remain critical elements of control efforts for HIV
infection and malaria, but resistance-mediating muta-
tions are common in P. falciparum in many areas, and key
questions remain inadequately answered. This study con-
sidered the following three major concerns regarding
daily use of TS in HIV-infected individuals.
First, did daily TS offer protection against malaria
despite the presence of anti-folate resistance-mediating
mutations? Five key resistance-mediating mutations,
which were already known to be common in much of East
Africa [25], were remarkably common in parasites iso-
lated from infected patients in this study. In this setting,
daily TS nonetheless offered strong preventive efficacy
against malaria. Thus, although the resistance-mediating
mutations may have mitigated the protective efficacy of
TS to some extent, the intervention nonetheless had a
pronounced effect. This result bodes well for Africa,
where the prevalence of these 5 key mutations is increas-
ing, but other mutations that mediate higher-level resis-
tance remain uncommon.
Second, did TS use select for parasites with additional
anti-folate resistance mediating mutations that might
ablate any protective efficacy of anti-folates? Blood sam-
ples were screened for the dhfr 164L mutation, which is
common in parts of South America and Asia [21], but has
not shown high prevalence in Africa. Recently, however,
the mutation was seen in 4% of parasites isolated in West-
ern Kenya [26], in 4.7% of parasites in Malawi from sub-
jects receiving SP [27], and 4-14% of symptomatic
subjects not receiving anti-folates in two low transmis-
sion highland regions of Western Uganda [28]. In this
study dhfr 164L was uncommon in HIV-uninfected chil-
dren who did not receive TS. However, compared to
those who did not receive the intervention, prevalence of
the dhfr 164L mutation was significantly greater in HIV-
infected children who received TS. These results indicate
that, in certain settings, daily TS may select for dhfr 164L.
The clinical significance of selection for this additional
mutation is unknown, but biochemical studies have
shown profound resistance in parasites harboring dhfr
164L [29]. However, it remains unclear whether the dhfr
164L mutation will spread in Africa. Indeed, as is the case
with some other resistance-mediating polymorphisms
that may engender a fitness cost (e.g. increased copy
number of the putative drug transporter gene pfmdr1),
the high level of anti-malarial immunity of populations in
areas of high malaria transmission in Africa may limit
selection for dhfr 164L [18]. The complete dhfr and dhps
genes were sequenced in a subset of samples and only one
additional polymorphism, the dhps 581G mutation, was
identified in 2 samples from children receiving daily TS.
This mutation has been associated with high-level in
vitro sulphadoxine resistance in P. falciparum [30], has
been seen in Southeast Asia and South America [30,31],
and had a prevalence of 55% in a recent study in northern
Tanzania [32]. In Kampala, the prevalence of the 581G
mutation was low, and it is unclear if it was selected by
daily TS. Importantly, no novel dhfr or dhps mutations
were identified.
Third, did the protective efficacy of TS decline over
time? In this study, TS efficacy was maintained over the
29-month observation period. This is not surprising
given the stability of the anti-folate-mediating mutations
assessed. Five of the 6 mutations evaluated were close to
saturated throughout the study period, while the preva-
lence of the 164L mutation, which is not yet widespread,
did not increase in those exposed or unexposed to TS.
The evolution of anti-folate resistance likely occurred
over several years, limiting the ability of the study to
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detect changes over the relatively short observation
period. Therefore, while the present study gives an indi-
cation that TS prophylactic efficacy may be sustained in
areas where background anti-folate resistance is exten-
sive, more studies will be needed to assess its longer-term
efficacy.
This study had some limitations. For ethical reasons,
HIV-infection and TS use could not be separated. There-
fore, comparisons of TS-unexposed and exposed partici-
pants were between HIV-uninfected children not
receiving TS and HIV-infected children receiving the
intervention. Sixteen percent of presumed HIV-unin-
fected subjects were not tested for HIV, as they had either
been excluded from the cohort prior to testing or
declined to be tested. However, the lack of HIV infection
among the 432 children who were tested suggests that
very few of the cohort, if any, had this infection, and any
bias resulting from misclassification of HIV status would
be expected to underestimate differences seen between
the HIV-infected and HIV-uninfected cohorts. The
impact of TS on 6 well characterized polymorphisms in
dhfr and dhps was considered in all samples, but due to
logistical constraints whole gene sequences were assessed
in only a subset of samples chosen based on amplification
and sequencing success; sequencing of only a portion of
the total might have introduced bias, and so it is possible
that other rare polymorphisms were missed. Finally, the
study was done in a relatively low transmission setting,
and findings may not be generalizable to other settings,
particularly those with higher malaria transmission
intensity. These limitations, however, do not alter the key
conclusions of the study, as noted above.
Conclusions
Considering impacts on malaria, this study strongly sup-
ports the use of TS prophylaxis in HIV-infected children
in Africa. Further, given the excellent protective efficacy
of TS, consideration might be given for its use in popula-
tions at highest risk of adverse consequences of malaria in
addition to other transmission reduction measures such
as ITNs. The study was not well-equipped to assess the
impact of daily TS on the selection of common anti-folate
resistance-mediating mutations, as these were already
very common at our study site. The findings of this study,
together with those from studies assessing SP efficacy for
IPTp, suggest that the prophylactic efficacies of TS and
SP remain high in even where anti-folate resistance is
widespread. However, the selection of an additional
mutation, dhfr 164L, in children receiving daily TS is con-
cerning, and suggests the need for continued surveillance
to monitor the protective efficacy of TS and the preva-
lence of resistance-mediating polymorphisms.
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